Literature DB >> 18622582

High levels of high sensitivity C-reactive protein predict the progression of chronic rheumatic mitral stenosis.

Omer Alyan1, Fatma Metin, Fehmi Kacmaz, Ozcan Ozdemir, Orhan Maden, Serkan Topaloglu, Ahmet Duran Demir, Zulkuf Karahan, Aziz Karadede, Erdogan Ilkay.   

Abstract

BACKGROUND: High sensitive C-Reactive Protein (hs-CRP) predicts morbidity and mortality in various clinical conditions. The effect of hsCRP on progression of chronic rheumatic mitral stenosis (CRMS) has not been demonstrated. METHODS AND
RESULTS: A total of 132 patients with CRMS (95 female, 37 male) and 145 control (100 female, 45 male) were included in the study. Baseline clinical, echocardiographic, hematologic and hs-CRP measurements were collected prospectively. Mean mitral valve area (MVA) was 1.4 +/- 0.3 cm(2), mean wilkins valve score value was 8.9 +/- 1.7, left atrial diameter was 5.0 +/- 0.7 cm, left atrial area was 37.2 +/- 12.6 cm(2), and systolic pulmonary arterial pressure (SPAP) was 44 +/- 11 mmHg in patients with CRMS. The mean levels of hs-CRP value, fibrinogen, and mean platelet volume (MPV) were significantly higher in CRMS group compared to control group. The levels of hsCRP were found to be positively correlated with mean Wilkins valve score value, SPAP, presence of atrial fibrillation (AF), left atrial diameter, left atrial area, presence of LASEC(+), fibrinogen, and MPV and inversely correlated with MVA in patients with CRMS. Linear regression analysis revealed that the hsCRP level independently affects mean Wilkins valve score value, left atrial area (LAA), LASEC(+) and AF in the patients with CRMS.
CONCLUSIONS: These results suggest that increased hsCRP levels are associated with CRMS severity. These association may be important when treating patients with CRMS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622582     DOI: 10.1007/s11239-008-0245-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  46 in total

1.  Relation of circulating C-reactive protein to progression of aortic valve stenosis.

Authors:  Pedro L Sánchez; Jose L Santos; Juan Carlos Kaski; Ignacio Cruz; Antonio Arribas; Eduardo Villacorta; Manuel Cascon; Igor F Palacios; Candido Martin-Luengo
Journal:  Am J Cardiol       Date:  2005-11-10       Impact factor: 2.778

2.  Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis.

Authors:  Luis M Moura; Sandra F Ramos; José L Zamorano; Isabel M Barros; Luis F Azevedo; Francisco Rocha-Gonçalves; Nalini M Rajamannan
Journal:  J Am Coll Cardiol       Date:  2007-01-22       Impact factor: 24.094

3.  Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

Authors:  F Haverkate; S G Thompson; S D Pyke; J R Gallimore; M B Pepys
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

4.  Ultrasonic backscatter from flowing whole blood. II: Dependence on frequency and fibrinogen concentration.

Authors:  Y W Yuan; K K Shung
Journal:  J Acoust Soc Am       Date:  1988-10       Impact factor: 1.840

5.  Color Doppler assessment of mitral regurgitation with orthogonal planes.

Authors:  F Helmcke; N C Nanda; M C Hsiung; B Soto; C K Adey; R G Goyal; R P Gatewood
Journal:  Circulation       Date:  1987-01       Impact factor: 29.690

6.  Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.

Authors:  G M Novaro; I Y Tiong; G L Pearce; M S Lauer; D L Sprecher; B P Griffin
Journal:  Circulation       Date:  2001-10-30       Impact factor: 29.690

7.  Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation.

Authors:  G T Wilkins; A E Weyman; V M Abascal; P C Block; I F Palacios
Journal:  Br Heart J       Date:  1988-10

8.  Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty.

Authors:  A Buffon; G Liuzzo; L M Biasucci; P Pasqualetti; V Ramazzotti; A G Rebuzzi; F Crea; A Maseri
Journal:  J Am Coll Cardiol       Date:  1999-11-01       Impact factor: 24.094

9.  Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves.

Authors:  M Olsson; C J Dalsgaard; A Haegerstrand; M Rosenqvist; L Rydén; J Nilsson
Journal:  J Am Coll Cardiol       Date:  1994-04       Impact factor: 24.094

10.  Increased preoperative C-reactive protein (CRP)-values without signs of an infection and complicated course after cardiopulmonary bypass (CPB)-operations.

Authors:  U Boeken; P Feindt; N Zimmermann; G Kalweit; T Petzold; E Gams
Journal:  Eur J Cardiothorac Surg       Date:  1998-05       Impact factor: 4.191

View more
  14 in total

1.  Effect of hydroxymethylglutaryl coenzyme-a reductase inhibitors on the long-term progression of rheumatic mitral valve disease.

Authors:  Francesco Antonini-Canterin; Luis M Moura; Roxana Enache; Elisa Leiballi; Daniela Pavan; Rita Piazza; Bogdan A Popescu; Carmen Ginghina; Gian Luigi Nicolosi; Nalini M Rajamannan
Journal:  Circulation       Date:  2010-05-03       Impact factor: 29.690

2.  Increased levels of markers of oxidative stress and inflammation in patients with rheumatic mitral stenosis predispose to left atrial thrombus formation.

Authors:  Vinay Kumar Pulimamidi; Vengatesan Murugesan; Medha Rajappa; Santhosh Satheesh; Kottenyen Thazhath Harichandrakumar
Journal:  J Clin Diagn Res       Date:  2013-11-10

3.  Factors associated with the development of atrial fibrillation in patients with rheumatic mitral stenosis.

Authors:  Mehmet Ozaydin; Yasin Turker; Ercan Varol; Sule Alaca; Dogan Erdogan; Nigar Yilmaz; Abdullah Dogan
Journal:  Int J Cardiovasc Imaging       Date:  2010-03-24       Impact factor: 2.357

4.  Association of matrix metalloproteinase 3 and endogenous inhibitors with inflammatory markers in mitral valve disease and calcification.

Authors:  Sonia Aloui; Wiem Zidi; Sana Ouali; Imen Guizani; Sameh Hadj-Taieb; Mohamed Sami Mourali; Moncef Feki; Monia Allal-Elasmi
Journal:  Mol Biol Rep       Date:  2018-10-09       Impact factor: 2.316

5.  Relation of hs-CRP and BNP levels with the atrial spontaneous echo contrast and thrombi in permanent atrial fibrillation patients with different etiologies.

Authors:  Tayfun Sahin; Eser Acar; Umut Celikyurt; Teoman Kılıc; Guliz Kozdag; Aysen Agacdiken; Dilek Ural
Journal:  Med Sci Monit       Date:  2012-02

Review 6.  Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.

Authors:  Richard Kones
Journal:  Drug Des Devel Ther       Date:  2010-12-09       Impact factor: 4.162

7.  The neutrophil to lymphocyte ratio is associated with severity of rheumatic mitral valve stenosis.

Authors:  Erkan Baysal; Cengiz Burak; Serkan Cay; Tolga Aksu; Bernas Altıntaş; Barış Yaylak; Utkan Sevük; Önder Bilge
Journal:  J Blood Med       Date:  2015-05-13

Review 8.  Biomarkers in Cardiology - Part 2: In Coronary Heart Disease, Valve Disease and Special Situations.

Authors: 
Journal:  Arq Bras Cardiol       Date:  2015-05-01       Impact factor: 2.000

9.  Mitral valve restenosis after percutaneous transmitral valvuloplasty, role of continuous inflammation.

Authors:  Mohammadali Ostovan; Amir Aslani; Shahima Abounajmi; Vida Razazi
Journal:  J Cardiovasc Thorac Res       Date:  2014-09-30

10.  Serum Levels of IL-17 and IL-23 in Patients With Rheumatic Mitral Stenosis.

Authors:  Mehmet Zihni Bilik; İbrahim Kaplan; Nihat Polat; Mehmet Ata Akil; Abdurrahman Akyüz; Halit Acet; Murat Yüksel; Ümit İnci; Fethullah Kayan; Nizamettin Toprak
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.